Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs.
about
Risperidone versus other atypical antipsychotics for schizophreniaOlanzapine versus other atypical antipsychotics for schizophreniaThe Scandinavian Solutions for Wellness study - a two-arm observational study on the effectiveness of lifestyle intervention on subjective well-being and weight among persons with psychiatric disordersEfficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study.Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injectionThe relationship between insight and subjective experience in schizophrenia.Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocolQuality of life as patient-reported outcomes: principles of assessment.The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial.Drug safety and efficacy evaluation of sertindole for schizophrenia.A computerized self-report symptom distress inventory: for use as a routine clinical interview in schizophrenia.The heterogeneity of antipsychotic response in the treatment of schizophrenia.Clinical Global Impression-severity score as a reliable measure for routine evaluation of remission in schizophrenia and schizoaffective disorders.Quality of life in schizophrenic patients.New antipsychotics, compliance, quality of life, and subjective tolerability--are patients better off?Quantifying clinical relevance in the treatment of schizophrenia.Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome.Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial.Neuroleptic dysphoria: revisiting the concept 50 years later.Adolescence, schizophrenia and drug abuse: a window of vulnerability.Subjective experiences on antipsychotic medications: synthesis and conclusions.Gender differences in remission and recovery of schizophrenic and schizoaffective patients: preliminary results of a prospective cohort study.QLiS--development of a schizophrenia-specific quality-of-life scale.Assessment of functioning in patients with schizophrenia and schizoaffective disorder with the Mini-ICF-APP: a validation study in Italy.Efficacy and tolerability of paliperidone ER in patients with unsatisfactorily controlled schizophrenia by other antipsychotics: a flexible-dose approachThe impact of subjective well-being under neuroleptic treatment on compliance and remission.Olanzapine: a 5-year perspective.Behavioral and emotional adverse events of drugs frequently used in the treatment of bipolar disorders: clinical and theoretical implications.AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures.Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia.Gender-specific Associations of the Brain-derived Neurotrophic Factor Val66Met Polymorphism with Neurocognitive and Clinical Features in SchizophreniaWhich rating scales are regarded as 'the standard' in clinical trials for schizophrenia? A critical review.Subjective Well-Being Under Neuroleptics Scale short form (SWN-K): reliability and validity in an Estonian speaking sampleLong-term Efficacy and Tolerability of Perospirone for Young Help-seeking People at Clinical High Risk: a Preliminary Open TrialDesign and Methodology of the Korean Early Psychosis Cohort Study.The RSM-scale: a pilot study on a new specific scale for self- and observer-rated quality of life in patients with schizophrenia.Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion.Subjective well-being in schizophrenia as measured with the Subjective Well-Being under Neuroleptic Treatment scale: a review.Treating patients with schizophrenia deficit with erythropoietin?Antipsychotic medication-induced dysphoria: its meaning, association with typical vs. atypical medications and impact on adherence.
P2860
Q24234950-3CF96CC0-4CAC-4FFC-86C1-325462840218Q24236545-294A5A65-BB45-4835-B5EF-B0ACA86DADEBQ33600231-634F316C-86F9-45E5-A741-5C5197779602Q33738740-86925F21-7A2E-4A7B-A96C-F60B1D2C3602Q33817737-61565FEB-44A6-4B56-8EEE-14BDA076EE91Q34005474-B6A51BED-3343-4A81-ACC0-82E141E1DBF8Q34041023-2645A92A-927D-432F-9176-EF86B2D50D43Q34074648-66CCAFC4-D578-4997-B8A3-E1F6735C85E3Q34113097-FDD4B46B-4DAE-4170-9A28-80337C9BDAE6Q34300628-E2D0E112-62B6-4555-B57A-F63A85B45C9CQ34359774-5CC00CDE-B37A-48C2-9EC4-00A91B0B65DBQ34831046-F545CC51-C0D8-4776-AD5E-6B1B1EEE55D9Q35096476-B680CAB8-1E48-4674-ABB5-B8715507ABB4Q35236921-BE1E706B-5239-4785-B8A4-8527E56B9C4EQ35805896-E976497B-1708-4EEE-8B57-80A5C4F1C81AQ35819467-471FEFE8-912F-43AA-BB11-7C8295FC2C4CQ35950793-C5C88146-99EF-4DBF-BA63-0D4099CFB012Q36033253-D077E8E5-B5F3-4197-B8ED-BE65A6ACD48CQ36118562-7450FF19-670A-46B0-8991-9BBB85A756BEQ36118566-4C6FDCC4-E643-4CA5-9910-8470F872E3E2Q36118569-13ECE04E-CD69-4F26-B2BD-49A1918D2945Q36169293-8757904D-6C12-4E0C-9836-5E39D85473E9Q36222726-33CD4537-5011-4594-BD3F-26E3E97E4652Q36234891-CFC5B253-4111-4996-AEB2-00A92A775EFFQ36294583-D924E496-10AB-4B23-AA35-BB8430E39AAFQ36460707-F5DF7A16-6D60-4F9D-B798-F19695410541Q36511290-F53CEEDF-664F-44DB-9FAF-7959DA3D09DEQ36582018-5D86ECA0-9CB1-498E-A780-9CF063ACFA57Q36738339-D24D1285-F586-45AC-A5F9-8EBFA68B98F7Q36981526-7D1AE4A4-A6DF-4ADE-BC28-70FB39664513Q37160615-8B4A1F9F-AE58-4F65-BA1A-7673DBB6A86AQ37300003-BD384875-2CED-4514-83FD-CC177FB0E1E4Q37357277-055F20C5-2078-4BBE-BBE7-82B10E8FE2A6Q37500576-411AB893-D579-4DF6-98EE-DE367BEDBAC6Q37589461-A636F026-5C6D-4170-81DE-81B3098C82BFQ37797948-047EC38C-EDCE-4654-960D-B8AEF92A2E3CQ37804880-AE7C5F59-9BA6-4526-B2E6-ADD28D503938Q37857856-9DA7773C-CCA0-46C3-BB50-EC11EA714CC9Q38020966-B75BB958-0E63-4325-BE3D-266B1E87E800Q38244017-1A72146A-7A43-4493-BBA9-184F43608355
P2860
Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Improvement of schizophrenic p ...... atypical antipsychotic drugs.
@en
Improvement of schizophrenic p ...... atypical antipsychotic drugs.
@nl
type
label
Improvement of schizophrenic p ...... atypical antipsychotic drugs.
@en
Improvement of schizophrenic p ...... atypical antipsychotic drugs.
@nl
prefLabel
Improvement of schizophrenic p ...... atypical antipsychotic drugs.
@en
Improvement of schizophrenic p ...... atypical antipsychotic drugs.
@nl
P2093
P1476
Improvement of schizophrenic p ...... atypical antipsychotic drugs.
@en
P2093
P356
10.1016/S0920-9964(00)00166-3
P407
P577
2001-05-01T00:00:00Z